During this period, FDA has stated it will not take enforcement action against compounders who continue to make tirzepatide products.) While it is highly likely that FDA will not address either Novo Nordisks or Eli Lilly and Companys submission until after the Proposed Rule is finalized, it is important that any entities compounding these drugs are aware that further changes to the rules may impact their ability to compound such drugs in the near future
According to NICE guidance (NG12), these red flags include unintentional weight loss, rectal bleeding, iron-deficiency anaemia, abdominal or rectal mass, persistent change in bowel habit (to looser or more frequent stools) for more than 6 weeks in people aged 60 or over, and a family history of bowel or ovarian cancer
HB, BC, DE, TM, PS, WS, MS, SW and NKZ wrote the manuscript
The study reports the use of inorganic selenium in rainbow trout to inhibit lipid peroxidation, inhibit antioxidant transcript levels, and inhibit blood glutathione levels
Cui Zhou D, Jayasinghe RG, Chen S, et al
The anticipated price reductions from Medicare negotiations may influence employer-sponsored health plans to adjust their coverage policies for GLP-1s